MedTrace Logo

Smoke-Free Living Study

NCT00832806 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-11-30

No results posted yet for this study

Summary

The goal of this study is to provide you with an effective treatment for reducing the physical and emotional stress that can occur during the early phase of being without cigarettes. It is our hope that this treatment will help you to stay smoke-free. You will receive counseling and a supply of Champix, a medication to help suppress the symptoms of nicotine withdrawal.

Purpose: To assess the effect of extended Integrated Voice Response (IVR) on smoking cessation after varenicline (Champix) and IVR treatment Hypothesis: There will be significant increase in participants who do not smoke at 1 year if extended IVR is used after 12 weeks of varenicline (Champix) and IVR treatment.

Conditions

  • Additional, Effective Methods to Stop Smoking

Interventions

BEHAVIORAL

Extended IVR (integrated voice response technology)

See detailed description

DRUG

Varenicline (Champix)

See detailed description

BEHAVIORAL

IVR treatment

See detailed description

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Jiri Frohlich, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00832806 on ClinicalTrials.gov